ArticleFrontiers in veterinary science2025
Case Report: Xenogeneic mesenchymal stem cell secretome for the treatment of feline chronic gingivostomatitis.
Article in Frontiers in veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Canine dental pulp stem cell-derived exosomes: Proteomic characterization and first xenogeneic application for post-castration wound healing in cats.Veterinary world · 2026Article
- Muse-like stem cell therapy for curing chronic diseases in geriatric feline and canine.Frontiers in veterinary science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case series describes the treatment of eight cats with mesenchymal stem cell (MSC) secretome, a therapeutic modality never used before for refractory feline chronic gingivostomatitis (FCGS). The cats were free of systemic illness and were not on immunomodulators during treatment. All cats received two to three treatments of MSC secretome through intramucosal injections given 3 months apart. White cell count and globulins, stomatitis disease activity index (SDAI), and histopathology were used pre- and post-treatment to assess the response to treatment. Of the eight selected cases, resolution of clinical signs and significant improvement of lesions were reported in two cats. Six cats did not have a substantial clinical response, and lesions remained mostly unchanged. Six cats had a reduction in globulins, and five cats increased in weight, respectively, after treatment. SDAI decreased in all the cats treated. The two cats that had resolution of clinical signs had the most significant decrease in serum globulins and SDAI, and both increased in weight. No adverse effects or chemistry and hematological abnormalities directly associated with the use of MSC secretome were observed in any of the cats, suggesting human-derived MSC secretome can be safely used in cats. Increases in weight and reductions in SDAI and globulinaemia were observed in a subset of cats after treatment, suggesting an immunomodulatory effect and downregulation of proinflammatory factors. Well-designed clinical trials are recommended to verify the observed effects in this study and to evaluate long-lasting clinical benefits or potential side effects of the treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.